ArticleJournal of scleroderma and related disorders2025

A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study.

Dinesh Khanna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.